Frequently Asked Questions
The global microcephaly market is projected to grow at a CAGR of 8.50% during the forecast period of 2022-2029.
Factors such as rising demand for oral drugs and increasing prevalence of breast cancer are acting as the major drivers for the global microcephaly market.
The major players operating in the Microcephaly Market are Merck KGaA (Germany), Novartis AG (Switzerland), Beckman Coulter Inc. (U.S.), bioMerieux (France), Bio-Rad Laboratories, Inc (U.S.), Danaher (U.S.), Hologic (U.S.), Inovio Pharmaceuticals (U.S.), Lonza (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.).
The major countries covered in the Microcephaly Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
